KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.

Yi-Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S K Mok

Int J Cancer 158(9) 2429-2439

PMID41474069
PMCIDPMC12963706
DOI10.1002/ijc.70265
发表日期2025-12-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the phase 3 KEYNOTE-042 China study of participants enrolled in China in the global KEYNOTE-042 (NCT02220894) and China extension (NCT03850444) studies, pembrolizumab improved overall survival (OS) versus chemotherapy in locally advanced or metastatic non-small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% (hazard ratio [HR], 0.63; 95% CI, 0.43-0.94), ≥20% (0.66; 0.47-0.92), and ≥1% (0.67; 0.50-0.89). We present outcomes from this study after 5 years of follow-up. Chinese participants with previously untreated locally advanced or metastatic NSCLC with PD-L1 TPS ≥1% without EGFR or ALK alterations were eligible. Participants were randomized 1:1 to pembrolizumab 200 mg every 3 weeks for up to 35 cycles or carboplatin plus paclitaxel or pemetrexed with optional pemetrexed maintenance (nonsquamous only). Primary endpoints were OS in the PD-L1 TPS ≥50%, ≥20%, and ≥1% subgroups. Median follow-up was 63.7 (range, 56.3-72.6) months among 262 participants (pembrolizumab, n = 128; chemotherapy, n = 134) included in this study. Pembrolizumab prolonged OS versus chemotherapy in participants with PD-L1 TPS ≥50% (HR, 0.65; 95% CI, 0.45-0.93), ≥20% (0.67; 0.49-0.91), and ≥1% (0.66; 0.51-0.87). Grade 3 to 5 treatment-related AEs occurred in 19.5% and 68.8% of participants in the pembrolizumab and chemotherapy groups, respectively. In conclusion, after 5 years of follow-up, pembrolizumab continued to demonstrate improved OS versus chemotherapy with manageable safety in Chinese participants with previously untreated locally advanced or metastatic NSCLC that expressed PD-L1. These data further support pembrolizumab monotherapy as a standard of care for these patients.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

FIGURE 1

FIGURE 1 Kaplan–Meier estimates of overall survival among participants with PD‐L1 TPS (A) ≥50%, (B) ≥20%, (C) ≥1%, and (D) 1%–49%. HR, hazard ratio; NR, not reached; PD‐L1, programmed cell death ligand 1; TPS, tumor proportion score.

A

Overall Survival

FIGURE 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
B

Overall Survival

FIGURE 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
C

Overall Survival

FIGURE 1 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
D

Overall Survival

FIGURE 1 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 2FIGURE 2 Treatment duration and time to response in participants who completed 35 cycles of pembrolizumab. BICR, blinded independent central review; BOR, best overall response; PD, progressive disease; PR, partial response; SD, stable disease.
非 KM Figure